Print View Attached Docs:
96310:ABL SEQUENCING
Alias Names:ABL Mutation Screening / BCR-ABL Sequencing / Imatinib (Gleevec) Resistance / TK Receptor
Methodology:Sequencing
Edit Date:4/13/2009
Performed:Once weekly
Released:7-10 days after setup at PeaceHealth Laboratories' reference lab.
CPT Code:83891-902B / 83894-902B / 83898-902B x2 / 83909-902B x2 / 83912-902B / 86902-902B
Specimen Collection Details
Collection:Six to seven 4 mL lavender top tube (EDTA) peripheral blood. Draw Monday-Thursday only. Also acceptable: Bone marrow. Note that the lower volume of bone marrow specimen reduces the number of cells and therefore the probability of detecting very low-level leukemia burdens in patients with minimal residual disease. media.
Handling:BLOOD: Stabilize peripheral blood by mixing with RPMI media in equal volumes of blood to media (1:1 ratio). Keep refrigerated. Indicate on the requisition the volume of RPMI tissue culture media used. Specimen MUST be received at PeaceHealth Laboratories' reference lab within 24 hours of collection.
BONE MARROW: Draw in a heparinized syringe and transfer to an EDTA collection tube. Mix with an equal volume (1:1 ratio) of RPMI. Keep refrigerated.
Stability:Unstable frozen.
Standard Volume:30 mL whole blood.
Minimum Volume:20 mL whole blood.
Transport:Refrigerated.
Comments:Direct sequencing of the ABL kinase domain.
Rejection Criteria:Clotted, frozen, or leaking specimen.

This test may require insurance company prior authorization before ordering.
Please check the prior authorization list
.
Failure to gain preauthorization may result in denial of coverage.